Are Drug Prices Too Low?

In the following video, Motley Fool health-care bureau chief Brenton Flynn discusses one criticism made by Eli Lilly CEO John Lechleiter of a problem facing big pharmaceutical companies in Europe: Drugs are too cheap. He specifically focuses on how differences in European health-care systems vs. those in the United States mean a lot of pressure to lower prices on pharmaceuticals in Europe, which is damaging to the industry.

Is Eli Lilly a buy or sell?
With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities, and reasons to buy and sell today. To find out more click here to claim your copy today.

The article Are Drug Prices Too Low? originally appeared on Fool.com.

Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.